AILT
MCID: ANG046
MIFTS: 52

Angioimmunoblastic T-Cell Lymphoma (AILT)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 12 54 60 56 15 17
Immunoblastic Lymphadenopathy 54 60 45 17
T-Cell Lymphoma, Aild Type 54 60
Lymphogranulomatosis X 54 60
Angioimmunoblastic Lymphadenopathy 74
Aitl 54
Ailt 60

Characteristics:

Orphanet epidemiological data:

60
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0111147
MeSH 45 D007119
NCIt 51 C7528
SNOMED-CT 69 835009
ICD10 34 C86.5
ICD10 via Orphanet 35 C86.5
UMLS via Orphanet 75 C0020981
Orphanet 60 ORPHA86886
UMLS 74 C0020981

Summaries for Angioimmunoblastic T-Cell Lymphoma

Disease Ontology : 12 A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis.

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to autoimmune lymphoproliferative syndrome, type v and b-cell lymphomas, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are T cell receptor signaling pathway and ICos-ICosL Pathway in T-Helper Cell. The drugs Vincristine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 autoimmune lymphoproliferative syndrome, type v 30.6 BCL6 TIA1
2 b-cell lymphomas 30.5 BCL6 MME SYK TIA1
3 composite lymphoma 30.4 BCL6 TIA1
4 lymphoma, hodgkin, classic 30.4 BCL6 MME
5 burkitt lymphoma 30.1 BCL6 CXCL13 MME
6 peripheral t-cell lymphoma 29.6 BCL6 CXCL13 ITK MME SYK TET2
7 angioimmunoblastic lymphadenopathy with dysproteinemia 11.8
8 lymphoma 11.3
9 diffuse large b-cell lymphoma 10.6
10 leukemia 10.5
11 heart lymphoma 10.3 BCL6 MME
12 arthritis 10.3
13 pure red-cell aplasia 10.3
14 pneumonia 10.3
15 vasculitis 10.3
16 hypereosinophilic syndrome 10.3
17 plasma cell leukemia 10.3
18 intravascular large b-cell lymphoma 10.3 BCL6 MME
19 testicular lymphoma 10.3 BCL6 MME
20 t-cell/histiocyte rich large b cell lymphoma 10.3 BCL6 MME
21 central nervous system hematologic cancer 10.3 BCL6 MME
22 acute salpingitis 10.2 CXCL13 MME
23 folic acid deficiency anemia 10.2 MME TET2
24 spondyloarthropathy 1 10.2
25 leukemia, chronic lymphocytic 2 10.2
26 leukemia, chronic lymphocytic 10.2
27 rheumatoid arthritis 10.2
28 ascites, chylous 10.2
29 mycosis fungoides 10.2
30 myelofibrosis 10.2
31 polyarteritis nodosa, childhood-onset 10.2
32 follicular lymphoma 10.2
33 hemophagocytic lymphohistiocytosis 10.2
34 thrombocytopenia 10.2
35 lymphocytic leukemia 10.2
36 cardiac tamponade 10.2
37 spondylitis 10.2
38 evans' syndrome 10.2
39 polyarteritis nodosa 10.2
40 leukemia, b-cell, chronic 10.2
41 methotrexate-associated lymphoproliferative disorders 10.2
42 nodular lymphocyte predominant hodgkin lymphoma 10.2 BCL6 PDCD1
43 marginal zone b-cell lymphoma 10.2 BCL6 MME
44 lymphoma, mucosa-associated lymphoid type 10.2 BCL6 CXCL13 MME
45 mature b-cell neoplasm 10.1 BCL6 MME
46 ileum cancer 10.1 MME TIA1
47 hashimoto thyroiditis 10.1
48 cryoglobulinemia 10.1
49 thyroiditis 10.1
50 lymphosarcoma 10.1

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 BCL6 CXCL13 ICOS ITK PDCD1 SYK
2 immune system MP:0005387 9.9 BCL6 CXCL13 ICOS ITK MAF MME
3 endocrine/exocrine gland MP:0005379 9.87 BCL6 ICOS ITK PDCD1 SYK TBX21
4 liver/biliary system MP:0005370 9.35 BCL6 MME PDCD1 SYK TET2
5 neoplasm MP:0002006 9.02 ICOS IDH2 PDCD1 TBX21 TET2

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 373)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
2
Ifosfamide Approved Phase 4,Phase 1,Phase 2,Early Phase 1 3778-73-2 3690
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 53-03-2 5865
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
7
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-02-2 5743
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 23214-92-8 31703
12
leucovorin Approved Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 6006 143
13
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable 51-75-2 4033
14
Methotrexate Approved Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 59-30-3 6037
16
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 31703
17
Pirarubicin Investigational Phase 4 72496-41-4
18
Isophosphamide mustard Phase 4,Phase 1,Phase 2,Early Phase 1 0
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
21 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
24 BB 1101 Phase 4,Phase 3,Phase 2,Early Phase 1
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
28 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
33 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
37 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Folate Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Vitamin B9 Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Vitamin B Complex Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
45
alemtuzumab Approved, Investigational Phase 3,Phase 1,Phase 2 216503-57-0
46
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
47
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
48 Orange Approved Phase 3
49
Clavulanate Approved, Vet_approved Phase 3,Not Applicable 58001-44-8 5280980
50
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613

Interventional clinical trials:

(show top 50) (show all 255)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
4 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL Recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
9 Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
10 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
14 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
17 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
18 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
19 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
20 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
21 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
22 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
23 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
24 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
25 Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
26 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
27 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
28 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
29 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
30 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
31 Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma Recruiting NCT03853044 Phase 2 Chidamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
32 Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) Recruiting NCT03273452 Phase 2 Chidamide
33 A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma Terminated NCT03070964 Phase 2 plitidepsin
34 Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma Terminated NCT00070291 Phase 2 cyclosporine
35 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
36 A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
37 Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) Active, not recruiting NCT01553786 Phase 2 Lenalidomide
38 Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Recruiting NCT03552692 Phase 2 Venetoclax
39 A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms Recruiting NCT03493451 Phase 2 BGB A317
40 Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma Recruiting NCT03590574 Phase 1, Phase 2
41 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
42 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
43 Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas Recruiting NCT02223208 Phase 1, Phase 2 Ro-CHOEP-21 (PHASE I);Ro-CHOEP-21 (PHASE II)
44 CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study Active, not recruiting NCT01719835 Phase 2 Cyclophosphamide;Gemcitabine;Doxorubicin;Vincristine;Prednisolone;methylprednisolone;Cisplatin
45 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
46 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
47 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Recruiting NCT02588651 Phase 2 Brentuximab vedotin
48 Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Recruiting NCT02232516 Phase 2 romidepsin;lenalidomide
49 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Etoposide;Prednisone
50 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Cochrane evidence based reviews: immunoblastic lymphadenopathy

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

42
T Cells, Bone, Bone Marrow, B Cells, Lymph Node, Endothelial, Liver

Publications for Angioimmunoblastic T-Cell Lymphoma

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 495)
# Title Authors Year
1
Angioimmunoblastic T-Cell Lymphoma. ( 30596215 )
2019
2
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. ( 30630534 )
2019
3
Guillain Barré syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma. ( 30648445 )
2019
4
Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation. ( 30732495 )
2019
5
Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases. ( 30809041 )
2019
6
Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma. ( 30861363 )
2019
7
Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma. ( 30861367 )
2019
8
Moving Toward Targeted Therapy in the Treatment of Angioimmunoblastic T-Cell Lymphoma. ( 30861369 )
2019
9
Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. ( 29493850 )
2018
10
A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma. ( 29048103 )
2018
11
Epstein-Barr virus clonality and plasmacytosis in a patient with atypical angioimmunoblastic T cell lymphoma. ( 29189897 )
2018
12
Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways. ( 29339730 )
2018
13
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
14
Florid Plasmacytosis in Angioimmunoblastic T Cell Lymphoma: A Diagnostic Conundrum. ( 29398831 )
2018
15
Hypercalcemia as a rare presentation of angioimmunoblastic T cell lymphoma: a case report. ( 29673407 )
2018
16
Secondary Cutaneous Epstein-Barr Virus-associated Diffuse Large B-cell Lymphoma with Hodgkin/Reed-Sternberg-like Cells in a Patient with Angioimmunoblastic T-cell Lymphoma. ( 29956714 )
2018
17
Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. ( 29909754 )
2018
18
The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH. ( 29621877 )
2018
19
Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. ( 29428971 )
2018
20
Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review. ( 29480865 )
2018
21
Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. ( 29197996 )
2018
22
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ( 29966769 )
2018
23
Angioimmunoblastic T-cell lymphoma: a rare subtype of peripheral T-cell lymphoma. ( 29636953 )
2018
24
Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. ( 29662631 )
2018
25
Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing. ( 29981867 )
2018
26
Methotrexate-associated lymphoproliferative disorders with angioimmunoblastic T-cell lymphoma-like features accompanied by gamma-heavy chain disease in a patient with rheumatoid arthritis. ( 29987858 )
2018
27
EBV-related Diffuse Large B-cell lymphoma in a Patient with Angioimmunoblastic T Cell Lymphoma: A Case Presentation. ( 30066674 )
2018
28
Chylous ascites, anti-interferon-gamma autoantibody, and angioimmunoblastic T-cell lymphoma: a rare but intriguing connection over Mycobacterium avium. ( 30083859 )
2018
29
Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma. ( 30097855 )
2018
30
Angioimmunoblastic T-cell lymphoma presenting with extensive marrow plasmacytosis and hypergammaglobulinaemia: a diagnostic challenge. ( 30143343 )
2018
31
B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. ( 30150635 )
2018
32
Hemophagocytic lymphohistiocytosis presenting with annular erythema multiforme-like eruptions in a patient with angioimmunoblastic T cell lymphoma: A case report. ( 30186440 )
2018
33
Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr Virus positivity and its effects on clinicopathological features. ( 30240776 )
2018
34
Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. ( 30279227 )
2018
35
Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B cell lymphoma or classical Hodgkin lymphoma: a histologic diagnostic pitfall. ( 30370547 )
2018
36
Angioimmunoblastic T-cell lymphoma mimicking diffuse large B-cell lymphoma. ( 30372708 )
2018
37
Antidiuretic hormone- and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion. ( 30485406 )
2018
38
Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome. ( 30557716 )
2018
39
Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome. ( 30592297 )
2018
40
Immunoglobulinopathies in patients with angioimmunoblastic T-cell lymphoma. ( 30701922 )
2018
41
Angioimmunoblastic T Cell lymphoma mimics reactive lymphoid tissue on cytomorphology: A multimodality approach utilising cytology, immunocytochemistry and flow cytometry to resolve this diagnostic dilemma. ( 28370552 )
2017
42
Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. ( 28148900 )
2017
43
A review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. ( 28889481 )
2017
44
Angioimmunoblastic T-Cell Lymphoma. ( 28340875 )
2017
45
Two cases of angioimmunoblastic T-cell lymphoma with concomitant positive serology for acute Epstein-Barr virus infection. ( 29071053 )
2017
46
Invasive aspergillosis in Refractory Angioimmunoblastic T cell lymphoma. ( 29129826 )
2017
47
Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor. ( 28953629 )
2017
48
A Rare Case of Angioimmunoblastic T-Cell Lymphoma with Epstein-Barr Virus-Negative Reed-Sternberg-Like B-Cells, Chylous Ascites, and Chylothorax. ( 28487786 )
2017
49
TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. ( 28337768 )
2017
50
Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma. ( 28194275 )
2017

Variations for Angioimmunoblastic T-Cell Lymphoma

Cosmic variations for Angioimmunoblastic T-Cell Lymphoma:

9 (show top 50) (show all 181)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6498677 WDFY3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5163A>T p.L1721F 4:84765835-84765835 0
2 COSM6987215 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1625C>T p.P542L 16:2065544-2065544 0
3 COSM10705 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.586C>T p.R196* 17:7674945-7674945 0
4 COSM43836 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.475G>C p.A159P 17:7675137-7675137 0
5 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.817C>T p.R273C 17:7673803-7673803 0
6 COSM43896 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.818G>C p.R273P 17:7673802-7673802 0
7 COSM10889 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.536A>G p.H179R 17:7675076-7675076 0
8 COSM45005 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.739A>G p.N247D 17:7674224-7674224 0
9 COSM10788 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.764T>G p.I255S 17:7674199-7674199 0
10 COSM10995 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 0
11 COSM45626 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.501G>T p.Q167H 17:7675111-7675111 0
12 COSM10654 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.637C>T p.R213* 17:7674894-7674894 0
13 COSM10687 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.527G>A p.C176Y 17:7675085-7675085 0
14 COSM10650 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.529C>T p.P177S 17:7675083-7675083 0
15 COSM35978 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.811C>T p.R271* 6:137877081-137877081 0
16 COSM6498674 TLR6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1828G>T p.D610Y 4:38827646-38827646 0
17 COSM6933803 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4075C>A p.R1359S 4:105269640-105269640 0
18 COSM43420 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4546C>T p.R1516* 4:105275056-105275056 0
19 COSM87190 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5696T>C p.L1899P 4:105276206-105276206 0
20 COSM211617 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3061C>T p.Q1021* 4:105237003-105237003 0
21 COSM7342039 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3921G>T p.R1307S 4:105259736-105259736 0
22 COSM41741 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5618T>C p.I1873T 4:105276128-105276128 0
23 COSM5945065 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4553C>G p.S1518* 4:105275063-105275063 0
24 COSM1660183 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4186T>C p.C1396R 4:105272567-105272567 0
25 COSM87108 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2692G>T p.G898* 4:105236634-105236634 0
26 COSM43499 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.5693C>T p.S1898F 4:105276203-105276203 0
27 COSM42040 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4240C>T p.Q1414* 4:105272621-105272621 0
28 COSM5945026 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2233C>T p.Q745* 4:105236175-105236175 0
29 COSM4766169 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3500G>A p.R1167K 4:105241429-105241429 0
30 COSM4766109 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.2861G>A p.W954* 4:105236803-105236803 0
31 COSM6023745 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4707C>A p.Y1569* 4:105275217-105275217 0
32 COSM100070 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.2887C>T p.Q963* 4:105236829-105236829 0
33 COSM5708963 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.3500G>T p.R1167M 4:105241429-105241429 0
34 COSM6987090 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.3817T>C p.C1273R 4:105259632-105259632 0
35 COSM7342041 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3320C>G p.S1107* 4:105237262-105237262 0
36 COSM7342042 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4069G>T p.E1357* 4:105269634-105269634 0
37 COSM7342035 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4402A>T p.K1468* 4:105272783-105272783 0
38 COSM7342034 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.3805A>T p.R1269* 4:105259620-105259620 0
39 COSM43417 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.2746C>T p.Q916* 4:105236688-105236688 0
40 COSM7342040 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3819T>G p.C1273W 4:105259634-105259634 0
41 COSM6023746 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3873G>A p.W1291* 4:105259688-105259688 0
42 COSM100058 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4333C>T p.Q1445* 4:105272714-105272714 0
43 COSM211727 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4019T>G p.L1340R 4:105261823-105261823 0
44 COSM7342037 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3892T>A p.C1298S 4:105259707-105259707 0
45 COSM100071 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4471A>T p.K1491* 4:105272852-105272852 0
46 COSM42016 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4393C>T p.R1465* 4:105272774-105272774 0
47 COSM4383929 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3954G>C p.E1318D 4:105259769-105259769 0
48 COSM6023743 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5636A>G p.E1879G 4:105276146-105276146 0
49 COSM5879027 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3896A>C p.K1299T 4:105259711-105259711 0
50 COSM110754 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4106C>G p.S1369* 4:105269671-105269671 0

Expression for Angioimmunoblastic T-Cell Lymphoma

Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.

Pathways for Angioimmunoblastic T-Cell Lymphoma

GO Terms for Angioimmunoblastic T-Cell Lymphoma

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell costimulation GO:0031295 9.16 ICOS PDCD1
2 cytokine production GO:0001816 8.96 ITK MAF
3 germinal center formation GO:0002467 8.62 BCL6 CXCL13

Molecular functions related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.62 ITK SYK

Sources for Angioimmunoblastic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....